Portfolio:

BioPulping International, Inc. is a start up company located in Madison, Wisconsin formed to develop and commercialize technologies mainly for the pulp and paper industry that would save electrical energy, improve paper quality, and reduce environmental impact of pulping, while producing value-added chemicals, such as ethanol, acetic acid etc. prior to pulping.

ConjuGon is developing fundamentally new therapeutics to combat the growing epidemic of antibiotic-resistant bacteria. Antibiotic resistance is a medical crisis, globally responsible for hundreds of thousands of deaths each year. ConjuGon's core technology is a new way to kill unwanted and even multi-drug resistant bacteria. ConjuGon's pipeline includes products for the treatment of wound infections and catheter-associated urinary tract infections.

Deltanoid Pharmaceuticals is a drug development company involved in breakthrough treatments for osteoporosis, renal osteodystrophy, psoriasis and other disease targets. The company specializes in designing advanced vitamin D analogs, including its lead compound DP001 which is currently being tested in a Phase II human clinical trial for the treatment of postmenopausal osteoporosis. Deltanoid will develop therapies at least through phase II human trials and will then consider entering into partnerships to conduct later stage human trials and to commercialize the therapies.

Flex Biomedical is a Madison, Wisconsin-based company that develops novel treatments and diagnostics for orthopedic diseases. The company has created a synthetic polymer which provides meaningful therapeutic affects for patients suffering from osteoarthritis, an incurable and painful joint disease in which cartilage and synovial fluid breakdown afflicts 200 million people worldwide.

Forte Research Systems, formerly PercipEnz Technologies, Inc. (name change announced WiSJ Sept. 29, 2010). Founded in 2000 and headquartered in Madison, Wisconsin, PercipEnz Technologies, Inc. develops and markets proprietary, enterprise-class clinical and translational research management systems for academic research organizations. By adopting a highly collaborative product development process, PercipEnz gathers, distills and fine-tunes the best ideas from world-class research institutions to deliver solutions addressing key operational challenges.

The company is host to Onsemble®, a community comprised of administrators, researchers, biostatisticians, research assistants, database administrators, and other staff from research facilities around the country.

GenTel BioSciences, Inc. is a commercial leader in biochip and protein microarray technologies. Since its inception in 2000, the company’s platform has focused on unique surface chemistry technologies for the purpose of detecting and measuring proteins. The application of proprietary miniaturized tests utilizing GenTel’s thin-film nitrocellulose surface has served to deliver new standards in biomedical discovery, medical care, and pre-clinical drug development.

GenTel is generating revenue through the sales of its novel multiplex immunoassays products and services. Its service business of developing and validating custom antibody arrays has expanded to include a fee-for-sample screening service called Aperateur™. These services include arraying specific antibodies or antigens, developing and validating specific assays, and screening pre-clinical and clinical samples.

GenTel's business has and continues to focus on protein microarray product and service excellence, driven by the delivery of protein microarray data you can trust.

GWC Technologies develops, manufactures and markets scientific instruments for life science and materials science research. The company’s SPRimager®II system is the leading array-based platform for label-free analysis of molecular interactions. Customers in commercial and academic sectors use this instrument to characterize antibodies, monitor protein-protein interactions, detect food contaminants, determine cell receptor profiles, and model drug absorption characteristics. GWC sells products direct in N. America, through select distributors abroad, and via OEM Partners Toyobo Co. Ltd. in Japan and Thermo Fisher Scientific worldwide.

Imago Scientific Instruments was acquired by CAMECA Science & Metrology Solutions, a division of Ametek, Inc., Berwyn, PA for $6,000,000 (WiSJ April 8, 2010).

NeoClone, LLC excels in the production of monoclonal antibodies. Using its proprietary retroviral approach in the development process, NeoClone can produce high affinity antibodies in significantly less time and at a dramatically lower cost than the rest of the industry. NeoClone is currently servicing the reagent and diagnostic markets and is enhancing its proprietary process to provide services to the therapeutic market.

Nerites Corporation was acquired January 31, 2011 by Kensey Nash Corp. of Exton, PA (Journal-Sentinel Online 1/31/11) for $20 million in cash. Nerites is developing novel medical devices based on technology derived from mussels from the ocean that are breakthroughs in providing new options for tissue repair and device coatings. Among the products being developed are:

• Tissue adhesive/sealant products for use as medical devices to bind tissue together
• Antibacterial coating products for medical devices

Cellectar, Inc closed a reverse merger with the publicly-owned Novelos Therapeutics, Inc. (NVLT) (Press Release April 11, 2011) and will assume the Novelos name. Headquarters will remain in Madison, WI. Novelos will continue to develop Cellectar’s three novel cancer-targeted compounds – designated HOT, COLD and LIGHT – which are selectively taken up and retained in cancer cells, including cancer stem cells.

nPoint, Inc. specializes in piezo actuator driven flexure stages available in one, two or three axes of motion. nPoint's ultra-precision motion control scanners and controllers provide users with the highest level of performance available in the marketplace. The company's product lines include standard products consisting of upgrade kits for Atomic Force Microscopy and stand alone research instruments, a diverse list of OEM applications and custom design for research applications.

Incept BioSystems announced to shareholders on December 17, 2010 its signing of a non-binding term sheet to sell all corporate assets to ORIGIO a/s of Copenhagen, Denmark for $300,000 to $1,050,000, plus some royalty payments, subject to certain milestones.

Performance Polymer Solutions Inc. (P2SI) was founded in 2002 to develop and commercialize high performance polymer products used primarily in aerospace and defense markets.  Since its inception P2SI has successfully launched a variety of new products, including polyimides for advanced composites, fiber sizings, thermally stable adhesives, preceramic polymers, and carbon nanofiber treated yarns and textiles.

Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Company’s Lead Candidate, QBI-139, is based on the Company’s EVade™ Ribonuclease Technology, which consists of a human pancreatic enzyme, Ribonuclease I engineered to kill cancer cells. The EVade™ Ribonuclease technology is covered by patents acquired by the Company through an exclusive license with the University of Wisconsin. The Company is in the late pre-clinical stages of development of QBI-139 and is on target to file an Investigational New Drug Application by the end of 2007. This enables a Phase I human clinical trial to begin early in 2008.

Renovar, Inc. was founded in 1999 by an internationally-recognized UW-Madison transplant surgeon. The company is developing diagnostic tests for kidney disease and transplant monitoring based on Renovar’s patented method. The company’s unique approach couples protein biomarkers and the company’s proprietary urine buffer system, which permits assaying of urine not possible otherwise. The method enables the potential for non-invasive, timelier disease detection with greater sensitivity and specificity.

Virent is an energy technology company that enables the renewable replacement of fossil fuels. Virent’s patented BioForming™ platform technology renewably produces liquid fuels, fuel gases, and many chemicals, all products most commonly made from fossil fuels. Based on the innovative Aqueous Phase Reforming (APR) pathway to biofuels and bioproducts, the BioForming process delivers more net energy and offers a scalable, cost-effective alternative to traditional biofuel production routes. The company’s current research initiatives center on developing production capabilities for biogasoline, sugar-based biodiesel, hydrogen, and propylene glycol.